Synarc
Synarc provides centralized medical imaging and molecular marker services for clinical trials, serving pharmaceutical sponsors, biotechs, and CROs running imaging-intensive drug development studies. Founded 1998.
- Company typePrivate
- Founded1998
- HeadquartersSan Francisco, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Synarc does
Synarc Inc. was founded in 1998 as a Maynard, Massachusetts-based provider of medical imaging and molecular marker services for clinical trials, serving pharmaceutical and biotechnology sponsors running imaging-intensive studies. Its core offering combined centralized imaging core lab capabilities and biomarker assays with operational workflows tailored to multi-site clinical trials. The firm pursued a roll-up strategy, including the July 2004 acquisition of IoDP, and was capitalized via venture funding — a $10.2 million round in March 2004 (led by SV Health Investors and U.S. Venture Partners) and a $5 million round in April 2008. Co-founder Harry K. Genant anchored the scientific leadership as Emeritus Chairman and Senior Consultant.
Synarc subsequently became part of BioClinica (per firmographic website linkage to bioclinica.com) and, through subsequent consolidation, contributed the medical imaging and molecular marker franchise to the broader clinical trial endpoint platform operated today as Clario. In its successor configuration the platform spans five endpoint categories — cardiac safety, eCOA, medical imaging, precision motion (Opal wearable), and respiratory — supported by a cloud-native architecture, connected devices, and AI-enabled tools (including Image Redact AI), deployed across 100+ countries. Revenue mechanics operate through enterprise service contracts with pharma sponsors, biotechs, and CROs at quote-based pricing tied to trial scope, therapeutic area, and phase, with recurring platform/device components supplementing project-based services. In October 2025 Thermo Fisher Scientific completed its acquisition of Clario Holdings Inc., folding Synarc's legacy capabilities into a broader laboratory and manufacturing services franchise.
Synarc firmographics
Firmographics- Name
- Synarc
- Website
- https://bioclinica.com
- Company type
- Private
- Founded year
- 1998
- Headcount range
- 5,001–10,000 employees
- Short description
- Synarc provides centralized medical imaging and molecular marker services for clinical trials, serving pharmaceutical sponsors, biotechs, and CROs running imaging-intensive drug development studies. Founded 1998.
- Ownership category
- akta.pro rank
Synarc industry classification
Industry- Product category
- Clinical Trial Imaging Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
- akta.pro secondary industries
- Clinical Research & Trial Central Laboratories (HLAFAMAL), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Synarc is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Synarc business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Clinical Trial Endpoint Technology Services: Provides proprietary endpoint technologies and evidence generation solutions to pharma sponsors, biotechs, and CROs conducting clinical trials. Revenue is generated through service contracts for cardiac safety, eCOA, medical imaging, precision motion, and respiratory solutions across all trial phases. The model combines technology platform fees, device/services pricing, and scientific/regulatory consulting services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Synarc product offering
Product offeringCore offering
Synarc Inc. is a provider of medical imaging and molecular marker services that supports pharmaceutical, biotechnology, and medical device sponsors running clinical trials. The company delivers centralized imaging core lab capabilities and biomarker/molecular marker analyses used as endpoints or surrogate endpoints in clinical studies. Its services are designed to generate quantitative, reproducible imaging and biomarker data to support drug development, regulatory submissions, and clinical research across therapeutic areas.
Product overview
Clario is a clinical trial endpoint technology company providing the most comprehensive evidence generation platform in the industry. The company offers a unified platform combining validated clinical trial management software, connected medical devices, and AI solutions. Core product categories include: Cardiac Solutions (arrhythmia analysis, blood pressure, ECG monitoring for Phase I-IV trials), eCOA (electronic clinical outcome assessments with specialized solutions like eCOA Swift for early-phase oncology and eCOA Rapid Start for faster trial setup), Medical Imaging (core lab services with AI-powered Image Redact AI), Precision Motion (Opal wearable sensor technology for mobility endpoints), Respiratory Solutions (spirometry, home testing, lung sound assessment), Trial Enablement (eligibility management, analytics, document management), and Clinical Adjudication. The platform supports site-based, hybrid, and decentralized clinical trials across 100+ countries with 24/7 support.
Differentiator
Problem solved
Functional benefit
Products and services
- Medical Imaging Services for Clinical Trials
- Molecular Marker Services
Quantifiable outcome
- 70% of FDA and EMA new drug approvals since 2015 involved Clario's technology
- +3 more outcomes
Companies that use Synarc
Customer profileSegments3 records
Ideal customer profiles1 record
Synarc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature8 records
Synarc partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights4 records
Synarc competitors and assessment
Company assessmentDirect peers
- IQVIA: IQVIA is the largest global CRO with extensive clinical trial endpoint technology, eCOA, and imaging capabilities. It is a direct competitor to the Synarc/Clario endpoint services business across pharma, biotech, and CRO customer segments.
- ICON plc: ICON, including PRA Health Sciences, offers a broad range of clinical research services including imaging, eCOA, and bioanalytical labs. It serves the same pharma/biotech client base as Synarc with overlapping endpoint service capabilities.
- Parexel International: Parexel is a global CRO offering clinical trial technology, imaging, and biomarker services with comparable CRO-and-biotech client mix to Synarc's clinical trial endpoint services.
- Medpace: Medpace is a mid-size clinical CRO with growing imaging, central lab, and eCOA capabilities serving biotech and mid-tier pharma, overlapping with Synarc's clinical trial endpoint service model for biotechs.
- BioTelemetry (Philips): BioTelemetry, now part of Philips, is a leader in cardiac safety services for clinical trials and a direct peer in the cardiac solutions and ECG monitoring business Synarc addresses.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a midsize CRO with scientific and endpoint expertise across multiple therapeutic areas, overlapping with Synarc's clinical research services and central laboratory model.
- Labcorp Drug Development: Labcorp (including Covance and early development/Fortrea spin) provides central laboratory and clinical trial services spanning biomarker testing, imaging, and bioanalytical work, directly competing with Synarc's central lab and clinical trial testing model.
Emerging players
- Calyx (formerly Parexel informatics): Calyx provides eCOA, imaging, and clinical trial technology solutions, with comparable endpoint technology focus and overlapping customer base in pharma and biotech sponsors.
- Signant Health: Signant Health is a clinical technology provider specializing in eCOA, ePRO, and patient-centric clinical trial solutions, competing directly in the digital clinical outcome assessment space that Clario's Synarc unit addresses.
Broad incumbents
- Charles River Laboratories: Charles River provides preclinical and clinical lab services including biomarker and central lab capabilities for clinical trials, comparable in central laboratory testing and biomarker analytical services to Synarc's molecular marker offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Synarc social profiles
Digital presenceSynarc compliance and trust
Trust signalCompliance3 records
Synarc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synarc leadership team
Management profileNumber of profiles
Profiles1 record
Synarc funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synarc M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synarc
What does Synarc do?
Synarc Inc. is a provider of medical imaging and molecular marker services that supports pharmaceutical, biotechnology, and medical device sponsors running clinical trials. The company delivers centralized imaging core lab capabilities and biomarker/molecular marker analyses used as endpoints or surrogate endpoints in clinical studies. Its services are designed to generate quantitative, reproducible imaging and biomarker data to support drug development, regulatory submissions, and clinical research across therapeutic areas.
When was Synarc founded?
Synarc was founded in 1998. It employs 5,001 to 10,000 people.
Where is Synarc based?
Synarc is headquartered in San Francisco, United States, in the North America region.
How does Synarc make money?
One revenue line is on record: clinical Trial Endpoint Technology Services.
Who are Synarc's main competitors?
Direct peers on record are IQVIA, ICON plc, Parexel International, Medpace, BioTelemetry (Philips), Worldwide Clinical Trials and Labcorp Drug Development. Emerging players are Calyx (formerly Parexel informatics) and Signant Health. Charles River Laboratories is listed as a broad incumbent.
Does Synarc have an API?
No public API is recorded for Synarc.
What industry is Synarc in?
Synarc's product category is Clinical Trial Imaging Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 5417 and its SIC code is 8071.